~5 spots leftby Apr 2026

Extended Mesenteric Excision for Crohn's Disease

Recruiting in Palo Alto (17 mi)
+1 other location
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Montreal General Hospital
No Placebo Group

Trial Summary

What is the purpose of this trial?

The study is looking at the role of the mesentery in disease recurrence for ileocolic Crohn's disease. It is a prospective study that has been designed to perform extended mesenteric excision on patients undergoing their first ileocolic resection for Crohn's disease. Endoscopic recurrence will be monitored with the hypothesis that patients receiving extended mesenteric ileocolic resection will have reduced endoscopic recurrence at 6 months after resection.

Research Team

Eligibility Criteria

This trial is for adults over 18 with Crohn's Disease affecting the distal ileum/ileocolic region, who haven't had previous ileocolic resections. It includes all forms of Crohn's presentations like stricturing and fistulizing. Those with prior surgeries in the area or disease in other sites, as well as those with intraabdominal sepsis, cannot participate.

Inclusion Criteria

I am over 18 years old.
I have not had surgery to remove part of my small and large intestine.
My Crohn's disease comes in various forms, including stricturing and fistulizing.
See 1 more

Exclusion Criteria

I have had surgery to remove part of my small and large intestine.
I have Crohn's disease in parts of my body other than the intestines.
I have an infection in my abdomen.

Treatment Details

Interventions

  • Extended Mesenteric Resection (Procedure)
Trial OverviewThe study tests if removing more of the mesentery (the tissue that attaches intestines to the back wall of the abdomen) during first-time surgery can reduce disease recurrence at six months post-surgery in patients with Crohn's Disease.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention ArmExperimental Treatment1 Intervention
Prospective study arm involving an extended mesenteric ileocolic excision.
Group II: Control ArmActive Control1 Intervention
Historical controls from a retrospective chart review of patients who had a limited ileocolic resection.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Montreal General Hospital

Lead Sponsor

Trials
20
Recruited
10,400+

Jewish General Hospital

Collaborator

Trials
144
Recruited
283,000+

Dr. Justin Cross

Jewish General Hospital

Chief Medical Officer since 2023

MD

Dr. Lawrence Rosenberg profile image

Dr. Lawrence Rosenberg

Jewish General Hospital

Chief Executive Officer since 2015

MSc and PhD in Experimental Surgery from McGill University, Master of Engineering from the University of Waterloo